Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Diabetes Technology and Therapeutics is Scopus-indexed (Q1, CiteScore 10.5), WoS SCIE. Published by SAGE Publications Ltd.
Checked against the index lists dated .
ISSN 1520-9156Verify ISSN ↗1557-8593Verify ISSN ↗
Publisher: SAGE Publications Ltd
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Medical Laboratory Technology | 1 / 42 | 98th | Q1 |
| Endocrinology, Diabetes and Metabolism | 27 / 250 | 89th | Q1 |
| Endocrinology | 15 / 132 | 89th | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1999–present, best quartile Q1, CiteScore 10.5.
Diabetes Technology and Therapeutics is Q1 in Medical Laboratory Technology (rank 1 of 42), Q1 in Endocrinology, Diabetes and Metabolism (rank 27 of 250) and Q1 in Endocrinology (rank 15 of 132), by CiteScore 2025.
Diabetes Technology and Therapeutics is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 10.5, which places it in quartile Q1 at the 98th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 2.663, quartile Q1, with an H-index of 116.
Diabetes Technology and Therapeutics is published by SAGE Publications Ltd. Its print ISSN is 1520-9156 and its online ISSN is 1557-8593.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Diabetes Technology and Therapeutics has an h-index of 131 and a 2-year mean of 5.31 citations per paper (OpenAlex). Its Scopus CiteScore is 10.5, quartile Q1. On 2-year citations it ranks #1 of 42 Scopus journals in Medical Laboratory Technology.
Diabetes Technology and Therapeutics published 216 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 94 research articles (2026), authors are most often from United States (39.9%), France (5.3%) and Denmark (4.7%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 6 retracted papers are recorded (1.5 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.